- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03618160
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Subcutaneous (SC) Injections of JNJ-64565111 in Healthy Male Japanese Participants and to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Participants
14. august 2019 oppdatert av: Janssen Pharmaceutical K.K.
A Double-blind, Placebo-controlled, Randomized, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Japanese Subjects and An Open-label, Single Dose Study to Assess Pharmacokinetics Following Subcutaneous Injections of JNJ-64565111 in Healthy Male Caucasian Subjects
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of JNJ-64565111 following single and multiple subcutaneous (SC) doses in healthy Japanese male participants.
Studieoversikt
Status
Avsluttet
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Faktiske)
42
Fase
- Fase 1
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Fukuoka, Japan, 812-0025
- Souseikai Hakata Clinic
-
Tokyo, Japan, 130-0004
- Sumida Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
20 år til 65 år (Voksen, Eldre voksen)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Mann
Beskrivelse
Inclusion Criteria:
- For Part 1 and Part 2, participant must be a Japanese male 20 to 65 years of age, inclusive, at the time of informed consent for screening. For Part 3, participant must be a Caucasian male (defined as white and all of his parents and grandparents are white as determined by participant's verbal report) 20 to 65 years of age, inclusive, at the time of informed consent for screening
- Participant must agree to use an adequate contraception method as deemed appropriate by the investigator; to always use a condom during sexual intercourse (even in case of prior vasectomy), or to remain abstinent, and not to donate sperm during the study and for 90 days after study drug administration. Participants should encourage their female partner to use an effective method of contraception (example, prescription oral contraceptives, contraceptive injections, intrauterine device, or contraceptive patch) in addition to the condom used by the male study participant
- Participant must have a body mass index (BMI) ranging from 25 to 40 kilogram per meter square (kg/m^2), weighing 120 kilogram (kg) or less
- Participant must be healthy on the basis of physical examination, medical history, vital signs, and 12 lead electrocardiogram (ECG) performed at screening
- Participant must be a non smoker for at least 1 month prior to screening. A positive urine smoking test (cotinine) at screening and/or admission (Day 2) will lead to exclusion
Exclusion Criteria:
- Participant having a history of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiovascular disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), significant pulmonary disease, including bronchospastic respiratory disease, hepatic or renal insufficiency, type 1 diabetes mellitus, type 2 diabetes mellitus (T2DM), diabetic ketoacidosis (DKA), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy, thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study result
- Participant has taken any prescription or nonprescription medication (including vitamins and herbal supplements), except for acetaminophen, from 14 days before the first dose of the study drug is scheduled until completion of the study
- Participant has received an experimental drug (including investigational vaccines) or used an experimental medical device within 3 months or within a period less than 5 times the drug's half life, whichever is longer, prior to screening
- Participant test positive for human immunodeficiency virus (HIV [positive serology for HIV antigen/antibody]), tests positive for hepatitis B virus surface antigen, or has antibodies to hepatitis C virus (HCV) at screening
- Participant has had major surgery (example, requiring general anesthesia) within 4 months before screening, or will not have fully recovered from surgery, or has surgery planned during the time the participant is expected to participate in the study or within 6 months after study drug administration
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Sekvensiell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Part 1: SAD (Cohort 1 to 3)
Participants in Cohorts 1 to 3 will receive a single Subcutaneous (SC) low, medium, and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants.
Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety, tolerability review to determine safe and maximum well tolerated dose.
|
Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions.
Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.
Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.
|
Eksperimentell: Part 2: MAD (Cohort 4 to 6)
Participants in Cohorts 4 to 5 will receive weekly multiple SC low and high dose of JNJ-64565111 or a JNJ-64565111 matched placebo respectively on Day 1, under fasted conditions in healthy Japanese male participants.
If multiple high dose is judged as not tolerable, additional optional Cohort 6 will be added to Part 2 to investigate the safety, tolerability and PK after administration of multiple medium dose of JNJ-64565111 in healthy Japanese male participants.
Doses in subsequent cohorts will be escalated based on review of Principal Investigator and the Sponsor's decision after safety and tolerability review to determine safe and maximum well tolerated dose.
|
Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions.
Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.
Participants will receive SC injection of matching placebo on Day 1 in all cohorts of Part 1 and on Days 1, 8, 15, and 22 in Part 2 under fasted conditions.
|
Eksperimentell: Part 3: Single Dose (Cohort 7)
Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 which may be started (as early as) in parallel with Cohort 3 in Part 1 on Day 1, under fasted conditions in healthy Caucasian male participants.
Based on the results from Cohort 1 to 3 in Part 1, the dose of Cohort 7 may be reduced to low dose or increased to high dose.
|
Participants in Cohorts 1 to 3 will receive a single SC low, medium, and high dose of JNJ-64565111 respectively on Day 1, participants in Cohorts 4 to 6 will receive weekly multiple SC low, high and medium dose of JNJ-64565111 respectively on Days 1, 8, 15, and 22, under fasted conditions.
Participants in Cohort 7 will receive a single SC medium dose of JNJ-64565111 on Day 1, under fasted conditions.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Part 1 and Part 3: Number of Participants With Adverse Events (AEs) as a Measure of Safety and Tolerability
Tidsramme: Up to Day 35
|
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product.
An AE does not necessarily have a causal relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.
|
Up to Day 35
|
Part 1: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Cmax is defined as the maximum observed serum concentration.
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 1: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Tmax is defined as the actual sampling time to reach maximum observed serum concentration of JNJ-64565111.
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 1: Area Under Serum Concentration Curve From Time 0 to Time of the Last Measurable Concentration (AUC[0-Last]) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
AUC(0-Last) is defined as the AUC from time 0 to the time of the last measurable (non-below quantification limit [non-BQL]) serum concentration.
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 1: Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC[0-Infinity]) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
AUC (0-infinity) is defined as the area under the serum concentration-time curve from time zero to infinite time calculated as the sum of AUC(0-last) and Clast/ lambda (z); wherein AUC(0-last) is area under the serum concentration time curve from time zero to last measurable serum concentration, Clast is the last observed measurable (non-BQL) serum concentration, and lambda (z) is the apparent terminal elimination rate constant.
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 1: Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
t1/2 is defined as the apparent terminal elimination half life, and is calculated as 0.693/lambda (z).
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 1: Apparent Volume of Distribution (V/F) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.
Apparent volume of distribution after subcutaneous dose (V/F) is influenced by the fraction absorbed and calculated as dose/(lambda (z)*AUC[0-infinity]).
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 1: Total Apparent Clearance (CL/F) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
CL/F is defined as the total apparent clearance of drug after extravascular administration calculated as: dose divided by AUC[0-infinity].
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 2: Number of Participants With AEs as a Measure of Safety and Tolerability
Tidsramme: Up to Day 72
|
An AE is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non investigational) product.
An AE does not necessarily have a causal relationship with the treatment.
An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non investigational) product, whether or not related to that medicinal (investigational or non investigational) product.
|
Up to Day 72
|
Part 2: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111
Tidsramme: Day 1: Predose, 8, 24, 48, 72, 120 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
|
Cmax is defined as the maximum observed serum concentration.
|
Day 1: Predose, 8, 24, 48, 72, 120 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
|
Part 2: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111
Tidsramme: Day 1: Predose, 8, 24, 48, 72, 120 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
|
Tmax is defined as the actual sampling time to reach maximum observed serum concentration of JNJ-64565111.
|
Day 1: Predose, 8, 24, 48, 72, 120 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
|
Part 2: Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111
Tidsramme: Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
|
t1/2 is defined as the apparent terminal elimination half life, and is calculated as 0.693/lambda (z).
|
Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
|
Part 2: Apparent Volume of Distribution (V/F) of JNJ-64565111
Tidsramme: Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
|
V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.
Apparent volume of distribution after subcutaneous dose (V/F) is influenced by the fraction absorbed and calculated as dose/(lambda (z)*AUCtau).
|
Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
|
Part 2: Total Apparent Clearance (CL/F) of JNJ-64565111
Tidsramme: Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
|
CL/F is the total apparent clearance of drug after extravascular administration calculated as: dose divided by AUCtau.
|
Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
|
Part 2: Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of JNJ-64565111
Tidsramme: Day 1: Predose, 8, 24, 48, 72, 120, 168 hours postdose; Day 22: 72, 96, 144, 168 hours postdose
|
AUCtau is defined as the measure of the serum drug concentration from time zero to end of dosing interval.
|
Day 1: Predose, 8, 24, 48, 72, 120, 168 hours postdose; Day 22: 72, 96, 144, 168 hours postdose
|
Part 2: Observed Serum Concentration Just Prior to the Beginning or the End of a Dosing Interval (Ctrough) of JNJ-64565111
Tidsramme: Day 8: Predose ; Day 15: Predose; Day 22: Predose, 168 hours postdose
|
Ctrough is defined as the observed serum concentration just prior to the beginning or the end of a dosing interval.
|
Day 8: Predose ; Day 15: Predose; Day 22: Predose, 168 hours postdose
|
Part 2: Average Concentration Over the Dosing Interval Tau (T) at Steady State (Caverage,ss) of JNJ-64565111
Tidsramme: Day 22: Predose, 72, 96, 144, 168 hours postdose
|
Caverage,ss is defined as area under the serum concentration time curve observed during a dosing interval (tau) at steady state) will be calculated as AUCtau/Tau.
|
Day 22: Predose, 72, 96, 144, 168 hours postdose
|
Part 2: Observed Accumulation Index (AR-AUC) of JNJ-64565111
Tidsramme: Day 1: Predose, 8, 24, 48, 72, 120, 168 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
|
AR-AUC is determined after multiple dose administration of JNJ-64565111 and calculated by using the equation: AUCtau, Day 22 divided by AUCtau, Day 1.
|
Day 1: Predose, 8, 24, 48, 72, 120, 168 hours postdose; Day 22: Predose, 72, 96, 144, 168, 312, 480, 720, 1200 hours postdose
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Part 1 and 3: Number of Participants With Anti-Drug Antibodies (ADAs) to JNJ-64565111
Tidsramme: Predose, 144 and 816 hours postdose
|
Number of participants with anti-drug antibodies (ADAs) to JNJ-64565111 will be reported.
|
Predose, 144 and 816 hours postdose
|
Part 1 and Part 3: Change From Baseline in Body Weight
Tidsramme: Baseline to Day 35
|
Change from baseline in body weight will be reported.
|
Baseline to Day 35
|
Part 1 and Part 3: Change from Baseline in Fasting Plasma Glucose (FPG) Levels
Tidsramme: Baseline to Day 35
|
Change from baseline in FPG levels will be reported.
|
Baseline to Day 35
|
Part 1 and Part 3: Change From Baseline in Total Cholesterol
Tidsramme: Baseline to Day 35
|
Change from baseline in total cholesterol will be reported.
|
Baseline to Day 35
|
Part 1 and Part 3: Change From Baseline in Low Density Lipoprotein- Cholesterol (LDL-C)
Tidsramme: Baseline to Day 35
|
Change from baseline in LDL-C will be reported.
|
Baseline to Day 35
|
Part 1 and Part 3: Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)
Tidsramme: Baseline to Day 35
|
Change from baseline in HDL-C will be reported.
|
Baseline to Day 35
|
Part 1 and Part 3: Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C)
Tidsramme: Baseline to Day 35
|
Change from baseline in VLDL-C will be reported.
|
Baseline to Day 35
|
Part 1 and Part 3: Change From Baseline in Triglycerides
Tidsramme: Baseline to Day 35
|
Change from baseline in Triglycerides will be reported.
|
Baseline to Day 35
|
Part 1 and Part 3: Change From Baseline in Free Fatty Acids
Tidsramme: Baseline to Day 35
|
Change from baseline in free fatty acids will be reported.
|
Baseline to Day 35
|
Part 2: Number of Participants With Anti-Drug Antibodies (ADAs) to JNJ-64565111
Tidsramme: Predose on Day 1, 8, 15, 22 and then at 144, 480, 720, 1200 hours postdose
|
Number of participants with ADAs to JNJ-64565111 will be reported.
|
Predose on Day 1, 8, 15, 22 and then at 144, 480, 720, 1200 hours postdose
|
Part 2: Change From Baseline in Body Weight
Tidsramme: Baseline to Day 72
|
Change from baseline in body weight will be reported.
|
Baseline to Day 72
|
Part 2: Change From Baseline in Fasting Plasma Glucose (FPG) Levels
Tidsramme: Baseline to Day 72
|
Change from baseline in FPG levels will be reported.
|
Baseline to Day 72
|
Part 2: Change From Baseline in Total Cholesterol
Tidsramme: Baseline to Day 72
|
Change from baseline in total cholesterol will be reported.
|
Baseline to Day 72
|
Part 2: Change From Baseline in Low Density Lipoprotein- Cholesterol (LDL-C)
Tidsramme: Baseline to Day 72
|
Change from baseline in LDL-C will be reported.
|
Baseline to Day 72
|
Part 2: Change From Baseline in High-Density Lipoprotein-Choelsterol (HDL-C)
Tidsramme: Baseline to Day 72
|
Change from baseline in HDL-C will be reported.
|
Baseline to Day 72
|
Part 2: Change From Baseline in Very Low Density Lipoprotein-Cholesterol (VLDL-C)
Tidsramme: Baseline to Day 72
|
Change from baseline in VLDL-C will be reported.
|
Baseline to Day 72
|
Part 2: Change From Baseline in Triglycerides
Tidsramme: Baseline to Day 72
|
Change from baseline in triglycerides will be reported.
|
Baseline to Day 72
|
Part 2: Change From Baseline in Free Fatty Acids
Tidsramme: Baseline to Day 72
|
Change from baseline in free fatty acids will be reported.
|
Baseline to Day 72
|
Part 3: Maximum Observed Serum Concentration (Cmax) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Cmax is defined as the maximum observed serum concentration.
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 3: Actual Sampling Time to Reach Maximum Observed Serum Concentration (Tmax) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Tmax is defined as the actual sampling time to reach maximum observed serum concentration of JNJ-64565111.
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 3: Area Under Serum Concentration Curve From Time 0 to Time of the Last Measurable Concentration (AUC[0-Last]) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
AUC(0-Last) is defined as the AUC from time 0 to the time of the last measurable non-below quantification limit serum concentration.
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 3: Area Under the Serum Concentration-Time Curve From Time 0 to Infinity (AUC[0-Infinity]) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
AUC (0-infinity) is defined as the area under the serum concentration-time curve from time zero to infinite time calculated as the sum of AUC(0-last) and Clast/ lambda (z); wherein AUC(0-last) is area under the serum concentration time curve from time zero to last measurable serum concentration, Clast is the last observed measurable (non-BQL) serum concentration, and lambda (z) is the apparent terminal elimination rate constant.
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 3: Apparent Terminal Elimination Rate Constant (Lambda [z]) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Lambda (z) is the apparent terminal elimination rate-constant, estimated by linear regression using the terminal log linear phase of the log transformed concentration vs time curve.
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 3:Apparent Terminal Elimination Half-Life (t1/2) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
t1/2 is defined the apparent terminal elimination half life, and is calculated as 0.693/lambda (z).
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 3: Apparent Volume of Distribution (V/F) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
V/F is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired serum concentration of a drug.
Apparent volume of distribution after subcutaneous dose (V/F) is influenced by the fraction absorbed and calculated as dose/(lambda (z)*AUC[0-infinity]).
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Part 3: Total Apparent Clearance (CL/F) of JNJ-64565111
Tidsramme: Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
CL/F is defined as the total apparent clearance of drug after extravascular administration calculated as: dose divided by AUC[0-infinity].
|
Predose, 1, 2, 4, 8, 12, 24, 36, 48, 72, 96, 144, 216, 384, 672, and 816 hours postdose
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Studieleder: Janssen Pharmaceutical K.K Clinical Trial, Janssen Pharmaceutical K.K.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
6. august 2018
Primær fullføring (Faktiske)
21. juni 2019
Studiet fullført (Faktiske)
21. juni 2019
Datoer for studieregistrering
Først innsendt
2. august 2018
Først innsendt som oppfylte QC-kriteriene
2. august 2018
Først lagt ut (Faktiske)
7. august 2018
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
16. august 2019
Siste oppdatering sendt inn som oppfylte QC-kriteriene
14. august 2019
Sist bekreftet
1. august 2019
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- CR108497
- 64565111NAS1001 (Annen identifikator: Janssen Pharmaceutical K.K)
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Sunn
-
Universidade do PortoFundação para a Ciência e a TecnologiaRekrutteringHealthy People-programmerPortugal
-
VA Office of Research and DevelopmentFullført
-
Universidad Católica del MauleFullført
-
University of MiamiJames and Esther King Biomedical Research ProgramAvsluttetHealthy Lifetime Ikke-røykereForente stater
-
Fundació Institut de Recerca de l'Hospital de la...FullførtHealthy People-programmerSpania
-
University of LeicesterNational Institute for Health Research, United KingdomFullførtPasienter med hjertesvikt og bevart ejeksjonsfraksjon - HFpEF | Pasienter med hjertesvikt med redusert ejeksjonsfraksjon - HFrEF | Healthy Controls Group - alders- og kjønnsmatchet
-
University Hospital, GrenobleUniversity Hospital, Clermont-Ferrand; Grenoble Institut des NeurosciencesAvsluttetParkinsons sykdom | Healthy Controls Group - alders- og kjønnsmatchetFrankrike
Kliniske studier på JNJ-64565111
-
Janssen Research & Development, LLCFullførtFedme og diabetes mellitus, type 2Forente stater
-
Janssen Research & Development, LLCFullført
-
Janssen Research & Development, LLCAvsluttetDiabetes mellitus, type 2Tyskland
-
Janssen Research & Development, LLCFullført
-
Merck Sharp & Dohme LLCRekrutteringNedsatt leverfunksjon | Ikke-alkoholisk SteatohepatittForente stater
-
Janssen Research & Development, LLCFullførtOvervektForente stater, Belgia, Storbritannia, Sverige, Polen, Canada
-
Janssen Research & Development, LLCFullførtNyresvikt, kroniskForente stater
-
Merck Sharp & Dohme LLCFullførtIkke-alkoholisk fettleversykdom | Ikke-alkoholisk SteatohepatittForente stater, Argentina, Australia, Canada, Frankrike, Israel, Italia, Korea, Republikken, Mexico, New Zealand, Polen, Den russiske føderasjonen, Spania, Taiwan, Tyrkia, Ukraina
-
Janssen Research & Development, LLCFullført
-
Merck Sharp & Dohme LLCRekrutteringIkke-alkoholisk fettleversykdom | NAFLD | Ikke-alkoholisk fettleversykdom | Ikke-alkoholisk Steatohepatitt | Fettlever, alkoholfriCanada, Forente stater, Puerto Rico, Israel, Japan, Korea, Republikken, Taiwan, Spania, Chile, Frankrike, Italia, Ungarn, Sveits, Belgia, Kina, Singapore, Tsjekkia, Portugal, Østerrike, Storbritannia, Thailand, Hong Kong, Tyrkia